100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
FA-BA304 Oncologie, Samenvatting Colleges $6.95
Add to cart
Quickly navigate to
Preview
  2.  
  3. Universiteit Utrecht (UU)
  4.  
  5. FA-BA304 Oncologie (FABA304)

Summary

FA-BA304 Oncologie, Samenvatting Colleges

2 reviews
 154 views  9 purchases
  • Course
  • FA-BA304 Oncologie (FABA304)
  • Institution
  • Universiteit Utrecht (UU)

In deze samenvatting zijn alle colleges uit collegejaar 2019/2020 samengevat. Het betreft zowel werk- als hoorcolleges. In de samenvatting is per besproken onderwerp/ ziektebeeld een algemene beschrijving van het ziektebeeld gegeven, subtypen, besproken mutaties, de casus indien die er was. En ...

[Show more]

Preview 4 out of 53  pages

Document information

  • March 11, 2021
  • 53
  • 2019/2020
  • Summary

Subjects

  • farmacie
  • farmacie
  • bachelor
  • bachelor
  • oncologie
  • fa ba
  • 304
  • ba304
  • onco
  • farmacie oncologie
  • pecorino
  • college

Written for

  • Universiteit Utrecht (UU)
  • Farmacie
  • FA-BA304 Oncologie (FABA304)
All documents for this subject (13)

2  reviews

review-writer-avatar

By: efie • 1 year ago

review-writer-avatar

By: Florian01 • 2 year ago

Seller

avatar-seller
Michelle1802

Reviews received

Content preview

FA-BA304
Oncologie
Samenvatting colleges




Michelle

,Inhoud
Dikke darmkanker .................................................................................................................................... 5
Algemene beschrijving dikke darmkanker........................................................................................................ 5
Subtypes dikke darmkanker ............................................................................................................................. 7
Vogel-gram ....................................................................................................................................................... 7
Besproken mutaties .......................................................................................................................................... 9
K-RAS mutatie ............................................................................................................................................... 9
B-RAF mutatie............................................................................................................................................... 9
Medicatie .......................................................................................................................................................... 9
Casus ............................................................................................................................................................... 10
Extra leerpunten uit de casus ..................................................................................................................... 11
Subtypering van kanker in het algemeen ................................................................................................... 11
Borstkanker ........................................................................................................................................... 12
Algemene beschrijving borstkanker ............................................................................................................... 12
Subtypen borstkanker .................................................................................................................................... 13
DNA reparatie systemen................................................................................................................................. 15
BRCA mutatie .................................................................................................................................................. 16
Medicatie ........................................................................................................................................................ 16
Casus ............................................................................................................................................................... 19
Huidkanker; melanoom .......................................................................................................................... 21
Algemene beschrijving melanoom ................................................................................................................. 21
Subtypen huidkanker ...................................................................................................................................... 22
Melanoom karakterisering ............................................................................................................................. 22
Besproken mutaties ........................................................................................................................................ 25
K-RAS mutatie ............................................................................................................................................. 25
B-RAF mutatie............................................................................................................................................. 25
KIT mutatie ................................................................................................................................................. 25
NF1 mutatie ................................................................................................................................................ 25
PTEN mutatie .............................................................................................................................................. 25
Medicatie ........................................................................................................................................................ 26
Casus ............................................................................................................................................................... 28
Eierstokkanker ....................................................................................................................................... 30
Algemene beschrijving.................................................................................................................................... 30



Michelle

2

, Subgroepen eierstokkanker............................................................................................................................ 30
Checkpoints .................................................................................................................................................... 30
G1-checkpoint ............................................................................................................................................ 30
G2-checkpoint ............................................................................................................................................ 31
M-checkpoint.............................................................................................................................................. 31
Medicatie ........................................................................................................................................................ 32
Casus ............................................................................................................................................................... 34
Resistentie ...................................................................................................................................................... 34
Longkanker; casus bespreking ................................................................................................................ 35
Longkanker algemeen..................................................................................................................................... 35
Symptomen van longkanker ....................................................................................................................... 35
Risicofactoren bij longkanker ..................................................................................................................... 35
Soorten longkanker .................................................................................................................................... 35
Stadia van longkanker ................................................................................................................................ 35
Levensverwachting bij longkanker ............................................................................................................. 36
Casus ............................................................................................................................................................... 36
Medicatie ........................................................................................................................................................ 38
Prostaatkanker; journalclub ................................................................................................................... 40
Prostaatkanker algemeen ............................................................................................................................... 40
Risicofactoren ............................................................................................................................................. 40
Levensverwachting ..................................................................................................................................... 40
Kaplan Meier curve ......................................................................................................................................... 40
Journal club..................................................................................................................................................... 40
Farmacokinetiek .................................................................................................................................... 42
Nanomedicijnen en advanced therapies in de oncologie .......................................................................... 43
Medicatie overzicht................................................................................................................................ 44
Alkylerende middelen ..................................................................................................................................... 44
Alkylsulfonderivaten ................................................................................................................................... 44
Oxazafosforinen.......................................................................................................................................... 44
Stikstofmosterderivaten ............................................................................................................................. 45
Overige alkylerende stoffen ....................................................................................................................... 45
Antimetabolieten............................................................................................................................................ 45
Foliumzuurantagonisten............................................................................................................................. 45




Michelle

3

, Purinederivaten .......................................................................................................................................... 46
Pyrimidine-antagonisten ............................................................................................................................ 47
Cytostatische antibiotica ................................................................................................................................ 48
Antracyclinederivaten ................................................................................................................................ 48
Overige cytostatiche antibiotica ................................................................................................................. 49
Antimitotische stoffen .................................................................................................................................... 49
Vinca-alkaloïden ......................................................................................................................................... 49
Taxanen ...................................................................................................................................................... 49
Topo-isomeraseremmers ............................................................................................................................... 50
Topo-isomerase-I remmers ........................................................................................................................ 50
Topo-isomerase-II remmers ....................................................................................................................... 50
Platinaverbindingen........................................................................................................................................ 50
Signaaltransductieremmers............................................................................................................................ 51
Monoklonale antilichamen......................................................................................................................... 51
Tyrosinekinase remmers ............................................................................................................................ 52
Overige signaaltransductieremmers .......................................................................................................... 52
Antihormonen ................................................................................................................................................ 52
Anti-androgenen ........................................................................................................................................ 52
Anti-oestrogenen........................................................................................................................................ 53
Aromataseremmers.................................................................................................................................... 53
Overige nieuwe oncolytica ............................................................................................................................. 53
PARP-inhibitors ........................................................................................................................................... 53
Checkpoint inhibitors overig....................................................................................................................... 53




Michelle

4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Michelle1802. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $6.95. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

52510 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$6.95  9x  sold
  • (2)
Add to cart
Added